Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Every week for the past year, Axios has published a map of where COVID cases are rising and falling in the U.S. Today, we retire our map because cases are decreasing nationwide, and have been for a while now. But COVID isn’t disappearing completely. So what will this next phase of the pandemic look like?

  • Plus, the big question mark hanging over the summer Olympics.
  • And, our skeptical space reporter explains why UFOs are having a moment.

Guests: Dr. Lauren Ancel Meyers, director of the COVID-19 Modeling Consortium at the University of Texas, and Axios' Ina Fried and Miriam Kramer.

Credits: Axios Today is produced in partnership with Pushkin Industries. The team includes Niala Boodhoo, Sara Kehaulani Goo, Dan Bobkoff, Alexandra Botti, Nuria Marquez Martinez, Sabeena Singhani, Amy Pedulla, Naomi Shavin, and Alex Sugiura. Music is composed by Evan Viola. You can reach us at podcasts@axios.com.

Go deeper:

Go deeper

Jun 2, 2021 - Podcasts

Grading Biden’s racial wealth gap plan

President Biden was in Tulsa, Oklahoma yesterday to mark 100 years since the Tulsa Race Massacre. While there, he announced a plan to tackle the racial wealth gap in the U.S., aimed at increasing home and small-business ownership in communities of color.

  • Plus, why some American visa holders are stranded in India.
  • And, CDC vaccine cards become de facto passports.
Updated 13 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Brendan Lynch/Axios

  1. Health: Emergency room visits of all kinds dropped amid the pandemic — NY smart-thermometer network could predict next COVID wave.
  2. Vaccines: FDA clears 10 million J&J vaccine doses from contaminated Baltimore plant — Moderna asks FDA to expand COVID-19 vaccine authorization to adolescents.
  3. Cities: Seattle becomes first major city to get 70% fully vaccinated — Schools nationwide prepare for packed kindergartens this fall.
  4. Work: Goldman Sachs requires U.S. employees to report vaccination status.
  5. Politics: U.S. to buy 500 million Pfizer doses to share with the world — State Department eases travel advisories for dozens of countries.
  6. World: Moscow orders new restrictions amid surge in COVID-19 cases — 12 Venezuela players, staff contract COVID-19 before Copa America opener — 2021 already has a higher global coronavirus death toll than 2020.
  7. 🎧 Podcast: Back to normal without herd immunity.
  8. Variant tracker: Where different strains are spreading.
55 mins ago - Health

Novavax says COVID-19 vaccine was 90% effective in Phase 3 trial

Photo: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

Novavax, a Maryland biotechnology company, announced Monday that its COVID-19 vaccine was 90.4% effective in its Phase 3 trial, including against coronavirus variants.

Why it matters: The study of 29,960 participants in the U.S. and Mexico found the shot was safe and highly effective, paving the way for the FDA to clear a 4th vaccine for emergency use by the end of the year.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!